PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Pediatr. Author manuscript; available in PMC Jul 1, 2010.
Published in final edited form as:
PMCID: PMC2743881
NIHMSID: NIHMS129220
The Association between Adiponectin/Leptin Ratio and Diabetes Type: The SEARCH for Diabetes in Youth Study
David M. Maahs, MD,1 Richard F. Hamman, MD, DrPH,1 Ralph D’Agostino, Jr, PhD,2 Lawrence M. Dolan, MD,3 Guiseppina Imperatore, MD, PhD,4 Jean M. Lawrence, ScD, MPH, MSSA,5 Santica M. Marcovina, PhD,6 Elizabeth J. Mayer-Davis, PhD,7 Catherine Pihoker, MD,8 and Dana Dabelea, MD, PhD1
1Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Denver, CO
2Wake Forest University School of Medicine, Winston-Salem, NC
3Cincinnati Children’s Hospital, Cincinnati, OH
4Center’s for Disease Control and Prevention, Atlanta, GA
5Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA
6Northwest Lipid Research Laboratory, Seattle, WA
7University of South Carolina School of Public Health, Columbia, SC
8Children’s Hospital and Regional Medical Center, Seattle, WA
Abstract
We tested the association of adiponectin/leptin ratio (ALR) with diabetes type after adjusting for multiple factors in 1,156 youth with newly diagnosed diabetes in the SEARCH study. Although ALR is associated with diabetes type in youth, it is due to differences in adiponectin, but not leptin levels.
Keywords: adiponectin, leptin, adiponectin/leptin ratio, type 1 diabetes, type 2 diabetes, pediatrics, youth
The adiponectin/leptin ratio (ALR) differ between type 1 and type 2 diabetes mellitus in youth(1) and may be a tool to distinguish between major diabetes types in youth(2). However, it is unclear whether ALR and its components are associated with diabetes type above and beyond differences in obesity. The objective of this study was to test the hypothesis that ALR is associated with diabetes type in analyses adjusted for demographic factors, A1c and obesity in a larger cohort of youth with diabetes.
A detailed description of the study methods in SEARCH has been published(3). SEARCH is a multi-center study conducting population-based ascertainment of diabetes in youth <20 years in the U.S. in racial/ethnically diverse populations. The study was approved by the local institutional review boards that had jurisdiction over the local study populations.
During the study visit, survey information was collected and blood was drawn fasting under conditions of metabolic stability for measurement of A1c and adipocytokines. Height, weight, and waist circumference were obtained(3). BMI z-score was calculated using a normalized standard deviation score(4). Diabetes type was based on health care provider’s report and validated with biochemical markers, including diabetes auto-antibodies and C-peptide in a subset(5). Of the 3,484 youth registered for SEARCH, 1,156 youth with newly diagnosed diabetes in 2002–2004 aged 3–19 years at diagnosis with complete data were included in this analysis. Race/ethnicity was self-reported using the 2000 U.S. census questions format. Adiponectin and leptin levels were measured using commercially available RIA assays with sensitivities of 1 ng/ml and 85.4 pg/ml, respectively.
Descriptive statistics (means/standard deviations or counts/percents) were calculated for variables of interest. Comparisons were made by diabetes type using t-tests or chi-squared tests for continuous and categorical variables, respectively. Next, a series of general linear models were fit to estimate mean levels of adipocytokines and ALR in type 1 and type 2 diabetic youth, adjusted for demographic factors, A1c, and obesity. In these models, because leptin and ALR were highly skewed, data were log transformed to make these variables more normally distributed. Four sequential models were fit: model 1) unadjusted, model 2) adjusted for age, sex, race/ethnicity, model 3) additionally adjusted for diabetes duration and A1c, model 4) additionally adjusted for BMI-z score and waist circumference. SAS software version 9.1 was used.
Our sample included 976 youth with type 1 and 180 with type 2 diabetes (Table). Compared with youth with type 2 diabetes, those with type 1 diabetes were younger (11.2±3.8 vs 15.3±2.6 years), had shorter diabetes duration (10.1±6.8 vs 11.3±7.6 months), were thinner (mean BMI z-score=0.57±0.99 vs 2.02±0.82), had less abdominal fat (mean waist circumference 67.1±12.1 vs 101.2±22.7 cm), and were more likely to be non-Hispanic White (75.9 vs 25.0%).
Table 1
Table 1
Characteristics of 1,156 Youth Recently Diagnosed with Type 1 or Type 2 Diabetes
Unadjusted adiponectin levels were higher in youth with type 1 than type 2 diabetes (18.22±0.22 vs 9.33±0.48, p<0.0001) and with sequential adjustments decreased slightly in type 1 youth and increased in type 2 (17.13±0.47 vs 13.85±0.65, p<0.0001) (Figure, A). Unadjusted leptin concentrations were much lower in type 1 as compared with type 2 youth (geometric mean 4.46±0.22 vs 17.81±1.79, p<0.0001) until adjusted for obesity (6.09±0.64 vs 5.50±0.99, p=0.20) (Figure, B).
Figure 1
Figure 1
1A, Adiponectin Level by Type of Diabetes; 1B, Leptin Level by Type of Diabetes; 1C, Adiponectin to Leptin Ratio (ALR) by Type of Diabetes
The unadjusted ALR was much higher in type 1 than in type 2 youth (geometric mean 3.79±0.23 vs 0.46±0.07, p<0.0001), and remained significantly higher after adjustment for demographics, duration of diabetes, A1c and then BMI-z and waist circumference (obesity markers), although the difference was substantially reduced (Figure, C; geometric mean 2.51±0.35 vs 1.97±0.56, p=0.0066).
ALR is significantly associated with diabetes type in youth after adjusting for multiple factors, including obesity. However, this difference is entirely driven by adiponectin levels, which remain significantly lower in youth with type 2 vs type 1 diabetes after multiple adjustment, whereas leptin concentrations were not different after adjustment for obesity.
Low adiponectin levels were shown to be associated with insulin resistance(6) and to predict cardiovascular disease in adults(7). Although adiponectin levels were shown to be lower in adults with type 2 diabetes compared with non-diabetic controls(6, 8), they were, paradoxically, higher in adults(9) and youth with type 1 diabetes(10). Adiponectin levels in youth with type 1 have been reported to be similar to controls at diagnosis, but increased at one month after diagnosis(11). In contrast, leptin was decreased at diagnosis and similar to control subjects one month after diagnosis(11). Another study has reported that leptin is higher in pubertal type 1 youth compared with controls(12). Little data exist on adipocytokines in youth with type 2 diabetes, but adiponectin seems to be lower(13) and leptin higher(14) in obese v non-obese youth.
In conclusion, our data suggest that ALR is associated with diabetes type above and beyond obesity. However this association is entirely due to differences in adiponectin, but not leptin levels. Adiponectin may be a useful measure of insulin resistance and help to better distinguish type 1 from type 2 diabetes in youth.
ACKNOWLEDGMENTS
The SEARCH for Diabetes in Youth Study is indebted to the many youth and their families, and their health care providers, whose participation made this study possible.
The authors wish to acknowledge the involvement of General Clinical Research Centers (GCRC) at the following institutions: Medical University of South Carolina (M01RR01070); Cincinnati Children’s Hospital (M01RR08084); Children’s Hospital and Regional Medical Center and University of Washington School of Medicine (M01RR00037 and M01RR001271); Colorado Pediatric GCRC (M01RR00069)
This study was funded by the Centers for Disease Control and Prevention (PA00097 and DP-05-069) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. The study sponsors have had no involvement in this study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication.
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
1. Morales A, Wasserfall C, Brusko T, Carter C, Schatz D, Silverstein J, et al. Adiponectin and leptin concentrations may aid in discriminating disease forms in children and adolescents with type 1 and type 2 diabetes. Diab Care. 2004;27:2010–2014. [PubMed]
2. Huerta MG. Adiponectin and leptin: potential tools in the differential diagnosis of pediatric diabetes? Rev Endocr Metab Disord. 2006;7:187–196. [PubMed]
3. SEARCH for Diabetes in Youth: a multicenter study of the prevalence, incidence and classification of diabetes mellitus in youth. Control Clin Trials. 2004;25:458–471. [PubMed]
4. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat. 2002;11:1–190. [PubMed]
5. Dabelea D, Bell RA, D'Agostino RB, Jr, Imperatore G, Johansen JM, Linder B, et al. Incidence of diabetes in youth in the United States. JAMA. 2007;27(297):2716–2724. [PubMed]
6. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–1935. [PubMed]
7. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–1737. [PubMed]
8. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–1599. [PubMed]
9. Maahs DM, Ogden LG, Snell-Bergeon JK, Kinney GL, Wadwa RP, Hokanson JE, et al. Determinants of serum adiponectin in persons with and without type 1 diabetes. Am J Epidemiol. 2007;166:731–740. [PubMed]
10. Barnes MM, Curran-Everett D, Hamman RF, Maahs D, Mayer-Davis EJ, D'Agostino RB, Jr, et al. Determinants of adiponectin levels in young people with Type 1 diabetes. Diabet Med. 2008;25:365–369. [PubMed]
11. Martos-Moreno GA, Barrios V, Soriano-Guillen L, Argente J. Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy. Eur J Endocrinol. 2006;155:757–761. [PubMed]
12. Celi F, Bini V, Papi F, Santilli E, Castellani MS, Ferretti A, et al. Circulating adipocytokines in non-diabetic and Type 1 diabetic children: relationship to insulin therapy, glycaemic control and pubertal development. Diabet Med. 2006;23:660–665. [PubMed]
13. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362–2374. [PubMed]
14. Blum WF, Englaro P, Hanitsch S, Juul A, Hertel NT, Muller J, et al. Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab. 1997;82:2904–2910. [PubMed]